IP valuation

There is increasing recognition of the potential of IP as an asset for investment, as a means of providing security for loans and for leveraging transactions. A significant problem is that of valuing IP. We offer valuations around the world – and all the due diligence, documenting, validity and scope research and portfolio assessments needed to support credible valuations – of intellectual property rights of all types including goodwill and other intangibles such as customer lists.

By working as a team our intellectual property legal and valuation experts can provide robust data and analysis, based on independent review and research to support the valuations given, adapted to the specific needs of the client or type of transaction involved.

We value all assets that must be individually accounted for under IAS38 and IFRS3. These include patents, brands, copyright, franchise and other IP licence agreements, trade secrets, customer lists and the like.

We offer strategic advice on how to maximise the value of the portfolios reviewed, provide budget and cash flow forecasts and assess licensing options and structures. We draft and advise on IP transaction documents to implement the strategic advice.

We make use of experienced multidisciplinary teams appropriate to the technology and IP assets in question to ensure a quick and value for money service, based on clear estimates and pricing, and with clear terms of business and statements of scope.

temp img
Christian Nguyen-Van-Yen
Partner

temp img
Ed Round
Partner

temp img
Kelvin King
Consultant

temp img
Maureen Kinsler
Partner

See more of our IP valuation specialists>

You may also be interested in...

.
Protect, enforce, commercialise
Article

Protect, enforce, commercialise

Agents, lawyers and consultants – under one roof

.
Articles

Accelerated Examination for Cancer Treatments at the USPTO: Part 3

Read the latest in our series examining the USPTO's pilot programme for accelerated examination of patent applications directed to methods of treating cancer with immunotherapy. 

POSTED 15 November 2017

Find the right person

Find the office that suits you

Click here to view our offices

>